Blog
RSS FeedPosted by Michael Wonder on 17 Jun 2020
Health Canada Approves Xtandi (enzalutamide) for the treatment of metastatic castration-sensitive prostate cancer
16 June 2020 - Xtandi is the first and only androgen receptor-axis-targeted therapy approved by Health Canada in three clinical ...
Posted by Michael Wonder on 15 Jun 2020
Sunovion announces Health Canada approval of Kynmobi (apomorphine hydrochloride) soluble film for the treatment of Parkinson's disease OFF episodes
15 June 2020 - First and only sublingual therapy approved for the on-demand treatment of Parkinson’s disease OFF episodes. ...
Posted by Michael Wonder on 12 Jun 2020
Health Canada issues notice of compliance for Bausch Health's Duobrii
11 June 2020 - Topical combination improving the sings and symptoms of plaque psoriasis in adult patients with moderate to ...
Posted by Michael Wonder on 10 Jun 2020
Sandoz Canada receives Health Canada approval to launch two oncology biosimilars: Ziextenzo and Riximyo
9 June 2020 - These two approvals mark an important milestone for Sandoz Canada, bringing its biosimilars into oncology at a ...
Posted by Michael Wonder on 28 May 2020
Health Canada approves birth control arm implant Nexplanon
26 May 2020 - A popular birth control implant that has long been advocated for use in Canada has now ...
Posted by Michael Wonder on 26 May 2020
Ofev (nintedanib) now available in Canada for adults living with progressive fibrosing interstitial lung diseases
25 May 2020 - Ofev slowed lung function decline in PF-ILD patients by 57% compared to placebo. ...
Posted by Michael Wonder on 06 May 2020
AbbVie receives Health Canada approval for the combination of Venclexta (venetoclax) with obinutuzumab for patients with previously untreated chronic lymphocytic leukaemia
5 May 2020 - Venclexta (venetoclax) plus obinutuzumab is the first chemotherapy-free, fixed-duration combination regimen approved by Health Canada for patients ...
Posted by Michael Wonder on 30 Apr 2020
Teva Canada announces the launch of Ajovy for the preventive treatment of migraine in adults who have at least four migraine days per month
29 April 2020 - Ajovy is the first and only anti-CGRP treatment with both quarterly and monthly dosing for the preventive ...
Posted by Michael Wonder on 29 Apr 2020
Health Canada approves Rozlytrek (entrectinib) for NTRK gene fusion-positive solid tumours in locally advanced or metastatic patients
28 April 2020 - Data show more than half of trial patients across all 10 tumour types studied had responses to ...
Posted by Michael Wonder on 21 Apr 2020
Alk announces Health Canada approval of Itulatek SLIT tablets for the treatment of tree pollen allergy
20 April 2020 - Over 20% of Canadians with allergies are impacted by tree pollen. ...
Posted by Michael Wonder on 19 Apr 2020
Knight Therapeutics announces approval of Ibrelsa in Canada
17 April 2020 - Knight Therapeutics announced that Health Canada has approved Ibrelsa (tenapanor) for the treatment of irritable ...
Posted by Michael Wonder on 17 Apr 2020
Health Canada approves an extended indication for Kisqali (ribociclib) in combination treatment
16 April 2020 - Breast cancer is the most common female cancer in Canada. ...
Posted by Michael Wonder on 08 Apr 2020
Advanced Accelerator Applications announces Health Canada approval of Netspot diagnostic imaging agent kit to detect neuroendocrine tumours
7 April 2020 - Netspot is the first and only kit for the preparation of gallium (68 Ga) oxodotreotide injection for ...
Posted by Michael Wonder on 21 Mar 2020
Janssen announces Health Canada approval of Cabenuva, the first long-acting regimen for the treatment of HIV
20 March 2020 - Cabenuva offers adults living with HIV a new once-monthly injectable option for maintaining viral suppression. ...
Posted by Michael Wonder on 10 Mar 2020
Health Canada approves fast-acting mealtime insulin, Fiasp, for children with diabetes
9 March 2020 - Health Canada also expands Fiasp approval to include insulin infusion pumps. ...